You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《藍籌業績》藥明康德(02359.HK)全年純利106.9億人民幣增21.3% 每10股派9.8336元人民幣
藥明康德(02359.HK)公布2023年度業績,實現收入403.41億人民幣(下同),按年增加2.5%。錄得純利106.9億元,增長21.3%,每股盈利3.64元。末期息每10股派9.8336元。 年內,綜合毛利163.73億元,上升12.9%;毛利率由上年度36.9%升至40.6%,經營效率提升及項目組合的變化助推毛利率提升,同時疊加匯率變化的有利影響。2023年止,剔除新冠商業化項目,公司在手訂單增長18%。 儘管面臨外部環境的不確定性,公司預計2024年收入介乎383-405億元,剔除新冠商業化項目後將保持正增長,預計增長率為2.7-8.6%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account